
Outcomes With Luspatercept Not Affected by Mutational Profile in MDS
Alternative approaches to management of low-risk myelodysplastic syndromes (MDS) have accumulated positive trial data and FDA approvals in recent years. During an in-person Case-Based Roundtable meeting for oncologists in Raleigh, North Carolina, Thomas W. …